Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday. Several other equities research analysts have also weighed in on the company. Piper Jaffray Companies reissued a “neutral” rating on shares of Ultragenyx Pharmaceutical in a research report on […]
